207 related articles for article (PubMed ID: 23679849)
1. Development of a high-throughput screening-compatible assay for the discovery of inhibitors of the AF4-AF9 interaction using AlphaScreen technology.
Watson VG; Drake KM; Peng Y; Napper AD
Assay Drug Dev Technol; 2013 May; 11(4):253-68. PubMed ID: 23679849
[TBL] [Abstract][Full Text] [Related]
2. MLL fusion partners AF4 and AF9 interact at subnuclear foci.
Erfurth F; Hemenway CS; de Erkenez AC; Domer PH
Leukemia; 2004 Jan; 18(1):92-102. PubMed ID: 14603337
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth.
Wu F; Nie S; Yao Y; Huo T; Li X; Wu X; Zhao J; Lin YL; Zhang Y; Mo Q; Song Y
Theranostics; 2021; 11(17):8172-8184. PubMed ID: 34373735
[TBL] [Abstract][Full Text] [Related]
4. t(4;11) leukemias display addiction to MLL-AF4 but not to AF4-MLL.
Kumar AR; Yao Q; Li Q; Sam TA; Kersey JH
Leuk Res; 2011 Mar; 35(3):305-9. PubMed ID: 20869771
[TBL] [Abstract][Full Text] [Related]
5. MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia.
Prange KHM; Mandoli A; Kuznetsova T; Wang SY; Sotoca AM; Marneth AE; van der Reijden BA; Stunnenberg HG; Martens JHA
Oncogene; 2017 Jun; 36(23):3346-3356. PubMed ID: 28114278
[TBL] [Abstract][Full Text] [Related]
6. The synthetic peptide PFWT disrupts AF4-AF9 protein complexes and induces apoptosis in t(4;11) leukemia cells.
Srinivasan RS; Nesbit JB; Marrero L; Erfurth F; LaRussa VF; Hemenway CS
Leukemia; 2004 Aug; 18(8):1364-72. PubMed ID: 15269783
[TBL] [Abstract][Full Text] [Related]
7. Crosstalk between 14-3-3θ and AF4 enhances MLL-AF4 activity and promotes leukemia cell proliferation.
Fioretti T; Cevenini A; Zanobio M; Raia M; Sarnataro D; Salvatore F; Esposito G
Cell Oncol (Dordr); 2019 Dec; 42(6):829-845. PubMed ID: 31493143
[TBL] [Abstract][Full Text] [Related]
8. Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes.
Biswas D; Milne TA; Basrur V; Kim J; Elenitoba-Johnson KS; Allis CD; Roeder RG
Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15751-6. PubMed ID: 21896721
[TBL] [Abstract][Full Text] [Related]
9. Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT.
Gessner A; Thomas M; Castro PG; Büchler L; Scholz A; Brümmendorf TH; Soria NM; Vormoor J; Greil J; Heidenreich O
Leukemia; 2010 Oct; 24(10):1751-9. PubMed ID: 20686504
[TBL] [Abstract][Full Text] [Related]
10. The heterodimerization domains of MLL-FYRN and FYRC--are potential target structures in t(4;11) leukemia.
Pless B; Oehm C; Knauer S; Stauber RH; Dingermann T; Marschalek R
Leukemia; 2011 Apr; 25(4):663-70. PubMed ID: 21233834
[TBL] [Abstract][Full Text] [Related]
11. An AF9/ENL-targted peptide with therapeutic potential in mixed lineage leukemias.
Barretto NN; Karahalios DS; You D; Hemenway CS
J Exp Ther Oncol; 2014; 10(4):293-300. PubMed ID: 25509985
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion gene.
Menendez P; Catalina P; Rodríguez R; Melen GJ; Bueno C; Arriero M; García-Sánchez F; Lassaletta A; García-Sanz R; García-Castro J
J Exp Med; 2009 Dec; 206(13):3131-41. PubMed ID: 19995953
[TBL] [Abstract][Full Text] [Related]
13. A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy.
Chen W; Li Q; Hudson WA; Kumar A; Kirchhof N; Kersey JH
Blood; 2006 Jul; 108(2):669-77. PubMed ID: 16551973
[TBL] [Abstract][Full Text] [Related]
14. AF4 and AF4-MLL mediate transcriptional elongation of 5-lipoxygenase mRNA by 1, 25-dihydroxyvitamin D3.
Ahmad K; Scholz B; Capelo R; Schweighöfer I; Kahnt AS; Marschalek R; Steinhilber D
Oncotarget; 2015 Sep; 6(28):25784-800. PubMed ID: 26329759
[TBL] [Abstract][Full Text] [Related]
15. The full transforming capacity of MLL-Af4 is interlinked with lymphoid lineage commitment.
Lin S; Luo RT; Shrestha M; Thirman MJ; Mulloy JC
Blood; 2017 Aug; 130(7):903-907. PubMed ID: 28637661
[TBL] [Abstract][Full Text] [Related]
16. Complex MLL rearrangements in t(4;11) leukemia patients with absent AF4.MLL fusion allele.
Kowarz E; Burmeister T; Lo Nigro L; Jansen MW; Delabesse E; Klingebiel T; Dingermann T; Meyer C; Marschalek R
Leukemia; 2007 Jun; 21(6):1232-8. PubMed ID: 17410185
[TBL] [Abstract][Full Text] [Related]
17. circRNA circAF4 functions as an oncogene to regulate MLL-AF4 fusion protein expression and inhibit MLL leukemia progression.
Huang W; Fang K; Chen TQ; Zeng ZC; Sun YM; Han C; Sun LY; Chen ZH; Yang QQ; Pan Q; Luo XQ; Wang WT; Chen YQ
J Hematol Oncol; 2019 Oct; 12(1):103. PubMed ID: 31623653
[TBL] [Abstract][Full Text] [Related]
18. The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression.
Xia ZB; Popovic R; Chen J; Theisler C; Stuart T; Santillan DA; Erfurth F; Diaz MO; Zeleznik-Le NJ
Proc Natl Acad Sci U S A; 2005 Sep; 102(39):14028-33. PubMed ID: 16169901
[TBL] [Abstract][Full Text] [Related]
19. The AF4-mimetic peptide, PFWT, induces necrotic cell death in MV4-11 leukemia cells.
Palermo CM; Bennett CA; Winters AC; Hemenway CS
Leuk Res; 2008 Apr; 32(4):633-42. PubMed ID: 17875318
[TBL] [Abstract][Full Text] [Related]
20. AAV8 vector expressing IL24 efficiently suppresses tumor growth mediated by specific mechanisms in MLL/AF4-positive ALL model mice.
Tamai H; Miyake K; Yamaguchi H; Takatori M; Dan K; Inokuchi K; Shimada T
Blood; 2012 Jan; 119(1):64-71. PubMed ID: 22025528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
